News

Mechanical blood clot removal led to good recovery in half of stroke patients


Research Highlights:

  • In a “real-world” international study comprising 1,000 patients, nearly half of stroke survivors achieved good to ideal outcomes at three months after the stroke if they had received mechanical clot removal.
  • For most patients in this study, only one attempt of mechanical clot removal was required.
  • The study also identified which types of blood clots – those rich in red blood cells and low in platelets – were linked to a greater likelihood of survival with less disability.

Embargoed until 11:25 a.m. CT/ 12:25 p.m. ET, Friday, Feb. 11, 2022

NewMediaWire) – February 11, 2022 – NEW ORLEANS – Mechanical removal of blood clots reduced post-stroke disability in nearly half of “all-comer” real-world stroke patients in an international study, according to preliminary late-breaking science presented today at the American Stroke Association’s International Stroke Conference 2022. The conference is a world premier meeting for researchers and clinicians dedicated to the science of stroke and brain health being held in person in New Orleans and virtually, Feb. 9-11, 2022.

The most common type of stroke, an ischemic stroke, is caused by a blood clot in a blood vessel that blocks the flow of blood to the brain. Treatment usually involves clot-busting medications to dissolve the clot. For severe stroke within a large blood vessel, the treatment also may include a procedure to remove the clot – called mechanical thrombectomy or endovascular therapy – in which a tiny tube, or catheter, equipped with a special device on the end, is threaded through the blood vessel to grasp the clot and remove it.

Previous studies found that stroke patients who received mechanical clot removal had less disability after three months than those who did not. However, these studies were performed in carefully selected centers and employed strict clinical and imaging inclusion criteria, which decreases the generalizability of their findings.

To examine the effectiveness of blood-clot removal across a wide range of stroke patients seen in routine daily care (outside of a clinical trial), the Embotrap eXtraction & Clot EvaLuation & Lesion Evaluation for NeuroThrombectomy, or EXCELLENT trial, enrolled 1,000 adult ischemic stroke patients (average age 70, 52% female) at 36 sites worldwide, from September 2018 to March 2021. The sites were a mix of Thrombectomy-Capable and Comprehensive Stroke Centers. Patients were treated with a specific mechanical thrombectomy device called EmboTrap in an unlimited time frame.

Notably, the study was designed to collect real-world treatment and did not exclude patients based on pre-stroke independence level, severity of stroke, location of the occlusion, or time between onset of stroke and treatment, researchers said (as per current guidelines mechanical thrombectomy treatment can be used within 24 hours of symptom onset in select patients). In addition, the study analyzed the characteristics of the removed blood clots and how that impacted stroke recovery.

The study found that most of the patients required only one attempt to remove the blood clot. However, it is common to require multiple attempts to completely remove the clot. In nearly half of all patients, clot removal resulted in slight/minimal disability (able to look after own affairs without assistance or no worsening from their pre-stroke condition), as gauged by a standard scale measuring level of disability 90 days after stroke.

“This study shows how much stroke thrombectomy has advanced,” said lead study author Raul G. Nogueira, M.D., director of the UPMC (University of Pittsburgh Medical Center) Stroke Institute and a professor of neurology and neurosurgery at the University of Pittsburgh School of Medicine. “We saw a wide range of cases, including patients who, not too long ago, would not be considered good candidates for thrombectomy based on older age, pre-existing disability or large size of the stroke on presentation. Our findings in this study expand thrombectomy to be considered for more stroke patients.”

The study also found blood clots that were rich in red blood cells and low in platelets resulted in less disability than blood clots composed of less red blood cells or those rich in red blood cells and high in platelet content.

Red blood cells contain the protein hemoglobin, which carries oxygen throughout the body. Fibrin is a protein, and platelets are cell fragments that help blood to clot, to help stop bleeding, however, in a stroke, clots block blood flow to the brain. Different proportions of these elements alter the blood clot consistency and its physical properties. This may facilitate or impair the clot removal procedure.

In this study, only 10% of patients whose clots had a higher composition of red blood cell count and a lower composition of platelets died within 90 days, compared to 24% of patients whose clots had a lower composition of red blood cells and platelets. Among patients with higher red blood cell content, 63% with lower platelet content had either slight or no disability, compared to 51% with higher platelet content.

“We knew that fibrin was associated with more difficult clot removal. However, this novel observation that platelets may modify clot properties is very intriguing,” Nogueira said. “The results may have potential implications for technique and device selection when removing clots and the development of better blood-clot removal strategies.”

Worldwide, stroke is the second-leading cause of death and a leading cause of long-term disability. Stroke is a medical emergency requiring immediate treatment, so it is important to recognize early signs and how to respond to them: Face drooping, Arm weakness, Speech difficulty, Time to call 9-1-1, remembered with the acronym F.A.S.T.

Co-authors are Adnan H. Siddiqui, M.D., Ph.D.; Albert J. Yoo, M.D., Ph.D.; Ricardo A. Hanel, M.D., Ph.D.; Osama O. Zaidat, M.D.; Werner Hacke, M.D., Ph.D.; Tudor Jovin, M.D.; Jens Fiehler, M.D.; Simon F. De Meyer, Ph.D.; Waleed Brinjikji, M.D.; Karen Doyle, Ph.D.; David S. Liebeskind, M.D., FAHA; Diogo C. Haussen, M.D.; Violiza Inoa, M.D.; William E. Humphries III, M.D.; Keith B. Woodward, M.D.; Pascal M. Jabbour, M.D.; Olivier François, M.D.; Hormozd Bozorgchami, M.D.; Elad I. Levy, M.D., M.B.A.; Stephan Boor, M.D.; Jose Cohen, M.D.; Shervin R. Dashti, M.D.; Muhammad A. Taqi, M.D.; Ronald F. Budzik, M.D.; Clemens M. Schirmer, M.D., Ph.D.; M. Shazam Hussain, M.D; Laurent Estrade, M.D.; Reade A. De Leacy, M.D.; Ajit S. Puri, M.D.; Rohan V. Chitale, M.D.; Caspar Brekenfeld, M.D.; Renu Virmani, M.D.; and Tommy Andersson, M.D., Ph.D. The list of authors’ disclosures is available in the abstract.

The study authors reported funding by Cerenovus, part of Johnson and Johnson.

Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association’s scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.

The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.

Additional Resources:

The American Stroke Association’s International Stroke Conference (ISC) is the world’s premier meeting dedicated to the science and treatment of cerebrovascular disease. ISC 2022 will be held in person in New Orleans and virtually, Feb. 9-11, 2022. The three-day conference will feature more than 1,500 compelling presentations in 17 categories that emphasize basic, clinical and translational sciences as research evolves toward a better understanding of stroke pathophysiology with the goal of developing more effective therapies. Engage in the International Stroke Conference on social media via #ISC22.

About the American Stroke Association

The American Stroke Association is devoted to saving people from stroke — the No. 2 cause of death in the world and a leading cause of serious disability. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat stroke. The Dallas-based association officially launched in 1998 as a division of the American Heart Association. Connect with us on stroke.org, Facebook, Twitter or by calling 1-888-4STROKE.

###

For Media Inquiries and AHA Expert Perspective:

AHA Communications & Media Relations in Dallas: 214-706-1173; ahacommunications@heart.org

Bridgette McNeill: bridgette.mcneill@heart.org

For Public Inquiries: 1-800-AHA-USA1 (242-8721)

heart.org and stroke.org



Source link

Show More

Related Articles

Back to top button